Barrick Mining Corporation Stock Price, News & Analysis

ETQ's global survey, The Pulse of Quality in Manufacturing 2024, reveals alarming trends in product recalls and promising developments in AI adoption. Key findings include:

- 73% of respondents experienced a product recall in the past five years, with costs reaching up to $99.9M per recall in the U.S.
- 47% plan to use AI in the next two years, while 33% are already using it
- 85% report that most or all plant floor workers have access to electronic devices
- 61% attribute up to half of product recalls to supplier issues
- 48% report 11-20 safety incidents annually

The survey, conducted by Censuswide, polled over 750 quality leaders across the U.S., U.K., and Germany. It highlights the growing role of frontline workers in decision-making and the strategic approach manufacturers are taking towards quality management.

BioArctic AB's partner Eisai reported that Leqembi® revenue more than doubled in Q2 2024, reaching JPY 6.3 billion, a 120% increase from Q1 2024 (JPY 2.8 billion). This resulted in a royalty of approximately SEK 43 million for BioArctic. Eisai leads Leqembi's development and regulatory submissions globally, with Eisai and Biogen co-commercializing the product. BioArctic has commercialization rights in the Nordic region and is preparing for joint commercialization with Eisai pending European approval. BioArctic's Q2 2024 report will be published on August 29, 2024, at 08:00 a.m. CET.

BioArctic AB's partner Eisai presented three-year data for lecanemab (Leqembi®) at the Alzheimer's Association International Conference 2024. Key findings include:

1. Increased patient benefit: Lecanemab reduced clinical decline by -0.95 on the CDR-SB scale after three years, up from -0.45 at 18 months.

2. Maintained safety profile: No new safety concerns observed over three years.

3. Early-stage patient improvement: 51% of patients with no or low tau showed improvement after three years.

4. Continued biomarker impact: Lecanemab positively affects biomarkers throughout treatment.

5. Tau spread reduction: Treatment slowed tau accumulation across brain regions.

These results suggest lecanemab's potential as a disease-modifying treatment for early Alzheimer's disease, with increasing benefits over time.

ETQ, part of Hexagon, achieved significant milestones in Q2 2024, reinforcing its leadership in the quality management system (QMS) market. Key highlights include:

1. Recognition: Named 'Overall Leader' among QMS suppliers by ABI Research.

2. Customer Growth: Added several new enterprise customers globally and expanded existing customer usage of ETQ Reliance®.

3. Industry Participation: Hosted the ETQ EU Summit and participated in major industry events like ASQ WCQI and Quality Show South.

4. Thought Leadership: ETQ executives shared insights at conferences and through industry publications.

These achievements demonstrate ETQ's commitment to innovation and customer satisfaction in the quality management landscape.

Barnes Aerospace has extended a long-term agreement with MTU Aero Engines AG, valued at $33 million. The deal involves Barnes Aerospace–Singapore OEM producing precision fabricated components for Pratt and Whitney's A320neo / A220 and Gulfstream G500 / G600 engines. This extension aligns with Barnes Aerospace's growth strategy to scale operations through deeper customer relationships and diverse capabilities.

The agreement highlights Barnes Aerospace's position as a key supplier in the industry, leveraging its high-precision technologies for high-volume production. Ian Reason, Senior VP of Barnes and President of Barnes Aerospace, emphasized the company's focus on operational and commercial excellence, which has led to MTU Aero Engines' continued confidence in their partnership.

Crawford & Company (NYSE: CRD-A and CRD-B) has announced a quarterly dividend declaration following its regular board meeting on July 25, 2024. The company will pay $0.07 per share for both Class A and Class B Common Stock. This dividend is payable on August 30, 2024, to shareholders of record as of the close of business on August 12, 2024. This announcement demonstrates Crawford & Company's commitment to providing regular returns to its shareholders, maintaining its dividend policy despite potential economic uncertainties.

BioArctic AB's partner Eisai announced plans to request re-examination of the Committee for Medicinal Products for Human Use (CHMP)'s negative opinion on the Marketing Authorization Approval for lecanemab, an Alzheimer's disease treatment, in the EU. The decision disappoints BioArctic's CEO, Gunilla Osswald, who emphasizes the importance of timely treatment for patients. Eisai has a 60-day period to provide grounds for re-examination, with CHMP having 60 days to respond.

Lecanemab is already approved in several countries, including the US, Japan, and China. Alzheimer's disease affects 6.9 million people in Europe, with projections indicating this number may double by 2050. BioArctic retains commercialization rights in the Nordic region, pending European approval.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on BioArctic AB's partner Eisai's Marketing Authorization Approval (MAA) for lecanemab, a treatment for Alzheimer's disease. This decision affects BioArctic's (Nasdaq Stockholm: BIOA B) potential to commercialize lecanemab in the Nordic region, which was contingent on European approval.

Lecanemab is already approved and marketed in several countries, including the United States, Japan, and China. BioArctic is consulting with Eisai regarding future actions and will provide an update later today. The negative opinion from CHMP represents a significant setback for BioArctic's European market plans for lecanemab in Alzheimer's disease treatment.

Barnes Group Inc. (NYSE: B) reported Q2 2024 financial results, showing sales of $382 million, up 13% year-over-year with organic growth of 5%. The company recorded an operating loss of $2.1 million due to a $53.7 million non-cash impairment charge in the Automation business unit. Adjusted operating income was $47.6 million, up 9%, with adjusted operating margin at 12.4%, down 40 bps. Adjusted EBITDA was $76.5 million, up 14%, with a margin of 20.0%, up 20 bps. Barnes reported a net loss of $46.8 million, or -$0.91 per share, compared to net income of $17.4 million, or $0.34 per share in the prior year. Adjusted EPS was $0.37, down 36% from $0.58 last year. The company updated its 2024 guidance, projecting organic sales growth of 4% to 6% and adjusted EPS of $1.55 to $1.75.